Table 2.
ox-LDL and TMAO serum levels of study participants before and after 2-month treatment.
| ox-LDL serum levels (μEq/L) |
Δ (%) | p-value | ||||
|---|---|---|---|---|---|---|
| Run-in (placebo) | Before treatment | After treatment | Follow-up | |||
| Group A | 1102.33 ± 398.43 | 1041.21 ± 406.76 | 249.2 ± 47.01 | 308.64 ± 52.57 | -76.06 | 0.03 |
| Group B | 822.99 ± 370.94 | 941.54 ± 316.01 | 244.6 ± 52.4∗ | 307.76 ± 100.77 | -74.02 | 0.02 |
|
TMAO serum levels (μM) |
Δ (%) | p-value | ||||
| Run-in (placebo) | Before treatment | After treatment | Follow-up | |||
| Group A | 3.47 ± 2.87 | 3.52 ± 2.95 | 0.75 ± 1.06 | 1.00 ± 0.99 | -78.58 | 0.006 |
| Group B | 3.42 ± 1.97 | 3.44 ± 2.04 | 0.80 ± 0.37# | 1.10 ± 0.44 | -76.76 | 0.001 |
Value are expressed as mean ± SD of three replicates. Decrement percentage between ox-LDL and TMAO serum levels before and after 8-week treatment was shown. Statistical significance is calculated by Student’s t-test. ∗P = 0.915, group A vs. group B (after treatment); #P = 0.897, group A vs. group B (after treatment). SD, standard deviation; TMAO, trimethylamine N-oxide.